-

Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo

Eastern Institute of Technology professor recognized for advancing PFAS and emerging contaminant analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health research.

Professor Cai is a globally recognized leader in environmental and bioanalytical chemistry. His research focuses on advancing analytical methods to detect trace environmental contaminants, including PFAS, endocrine-disrupting chemicals, and persistent organic pollutants. By combining high-sensitivity analytical techniques with organoid-based toxicological models, his work aims to improve understanding of how environmental contaminants affect human health.

The awarded research combines advanced mass spectrometry techniques, innovative sample preparation methods, and organoid-based toxicology platforms to link chemical detection with biological impact. Professor Cai's team aims to develop a more comprehensive framework for assessing environmental contaminants and their potential health effects.

“PFAS and other emerging contaminants are increasingly recognized as critical environmental and public health challenges worldwide. Detecting these contaminants at trace levels requires continuous innovation in analytical science. Agilent has played a pioneering role in addressing PFAS background contamination, setting an important foundation for high-quality PFAS analysis. Through the ARC program, we are excited to expand our research using Agilent’s advanced mass spectrometry and cellular analysis platforms to develop new approaches for trace contaminant detection and organoid-based toxicological studies. We hope this collaboration will contribute impactful scientific advances that strengthen the connection between analytical science and environmental health research,” said Professor Zongwei Cai.

“Professor Cai’s research exemplifies the kind of scientific innovation the ARC program is designed to support,” said Ting Yang, vice president and general manager of Agilent Greater China. “Over the years, it has been a privilege to witness the continued advancement and impact of his work in environmental and bioanalytical chemistry. Agilent is proud to support his pioneering research in PFAS and emerging contaminant analysis, and we warmly congratulate Professor Cai and his team on this well-deserved recognition.”

The ARC Award includes research funding and Agilent instrumentation, enabling Professor Cai's team to advance analytical methods for contaminant detection and toxicological assessment. These insights will help scientists improve environmental monitoring, support risk assessment efforts, and better understand the effects of environmental contaminants on human health.

This collaboration exemplifies Agilent's commitment to advancing scientific discovery through partnerships with leading researchers around the world. Through the ARC program, Agilent provides financial support, advanced instrumentation, and scientific expertise to accelerate innovation in life sciences, environmental analysis, diagnostics, and chemical analysis.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

MEDIA CONTACT:
Christian Colón
+1 302-867-4117
christian.colon@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT:
Christian Colón
+1 302-867-4117
christian.colon@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo...

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD...

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb’...
Back to Newsroom